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Goal:
To describe the risks associated with the concomitant 
use of opiate and benzodiazepine medications.  
Objectives:
List the pharmacodynamic interactions between the 
opiate and benzodiazepine (BZD) class of drugs, 
Identify the physiological presentation 
of benzodiazepine and opiate combination use, 
Describe possible benefit of this combination of 
medications, and 
Explain when this combination of medication classes 
presents a risk to the patient.
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• In patients abusing opiates rates are nearly 75% concomitant use.
• 72% of methadone users who were coprescribed BZDs found the BZD 
enhanced the opiate effect.
– More commonly seen in in-treatment patients compared to untreated 
heroin users.
• In methadone maintenance treatment pts rates are over 50%.
– Buprenorphine treated pts have similar rates.
• Some pts are legally prescribed BZDs but most are using illegally.
– Also results in worse w/d syndrome.
• In chronic pain approximately 33% opiate and BZD coprescribed.
Backmund M. J Addict Dis. 2005.
Jones JD. Drug Alc Dep. 2012.
Manchikanti L. Pain Physician. 2013.
Frequency of concomitant use
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• 2002-2009 Primary care clinics are increasing 
BZD and opiate prescriptions, both 
monotherapy and as combination therapy.
– 12% increase in coprescribing.
– Same trend is also seen in ED rxs. 
• 6.4% inc in coprescribing.
• Often started from 2 separate prescribers then 
continued by new prescriber.
Kao M. Poster presentation AAPM 30th Annual Meeting. 2014.
Increase in prescribing 
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Agonism at specific opiate receptors
• 
– Analgesia
– Decreased respiratory function
– Decreased GI motility
– Increased feeding
– Increased sedation
– Increased prolactin release
– Increased growth hormone release
– Inhibit acetylcholine release
– Inhibit DA release
Goodman and Gilman’s Pcol Basis of Therapeutics. 11th ed.2006.
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Agonism at specific opiate receptors
• 
– Analgesia
– Decreased GI motility
– Psychotomimesis
– Increased feeding
– Increased sedation
– Increased diuresis
• 
– Analgesia
– Increased feeding
– Increased growth hormone
– Inhibit DA release
Goodman and Gilman’s Pcol Basis of Therapeutics. 11th ed.2006.
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• Not as easily defined as with opiate 
subtypes
– Approx 19 subtypes
– GABAA
•  1-6,  1-3,  1-3, , , , , p 1-3
–p 1-3 sometimes referred to as GABAc
– GABAB
• 1 and 2
Rudolph U. Curr Opin in Pharmacol. 2006.
Whiting PJ. Curr Opin in Pharmacol. 2006.
Bowery NG. Curr Opin in Pharmacol. 2006.
GABA agonism
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• GABAA
– 
• Sedative/hypnotic, reinforcing
– 2 and 3
• Anxiolytic, anticonvulsant (2)
– 5
• Learning and memory
– 3 
• Respiratory drive, hypnotic
• GABAB
– Muscle relaxant
Fradley RL. J Psychopharmacology. 2007.
Rudolph U. Current Opin Pharmacology. 2006.
Bowery NG. Current Opin Pharmacology. 2006.
GABA receptor subtype and effect
9
| |
Dynamic effects of opiate and 
benzodiazepine (BZD)
• Respiratory depression
– Most significant harm related to combo use.
– Due to 2 mechanisms.
• Primary: Additive effect on lowering respiratory drive.
– Both through GABA effects and possible pro opiate 
effects from the BZD.
• Possible increase in opiate levels (kinetic).
• Diazepam and methadone combination produced greater 
miosis (pupillary constriction) then either monotherapy.
Preston KL. Clin Pharmacol Ther. 1984.
Kapur BM. Critical Rev in Clin Lab Sci. 2011.
Jones JD. Drug Alc Dep. 2012.
Backmund M. J Addict Dis. 2005.
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Physiological effects of combo
placebo v alprazolam 0.5mg v oxycodone 10mg v combo.
• Miosis (mm)
– pl 6.7, alpraz 6.6, oxy 5.5, combo 5.1
• SaO2
– Pl 97.9, alpraz 97.6, oxy 97.7, combo 96.9
• Altered sense
– Feeling high (0-100)
• Combo increased 33% compared to oxy mono
• Combo increased 500% compared to alpraz mono
Zacny JP. Drug Alc Dep. 2012
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Opiate kinetics
• CYP 3A4
– Methadone
– Buprenorphine
– Oxycodone to oxymorphone
– Fentanyl
• CYP 2D6
– Codeine
– Hydrocodone to hydromorphone
• Glucuronidation
– Morphine
– Oxymorphone
– Hydromorphone
Armstrong SC. Psychosomatics. 2009.
Pergolizzi JV. JMCP. 2014.
Overholser BR. Amer J Manag Care. 2011.
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BZD pharmacokinetics
• CYP 450 3A4
– Alprazolam
– Midazolam
– Triazolam
– Chlordiazepoxide
• CYP 450 2C19
– Diazepam (and 3A4)
• Glucuronidation
– Oxazepam
– Lorazepam
Textbook of Psychopharmacology 4th ed. 2009.
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Opiate and BZD kinetic interactions
• Midazolam and diazepam increase 
methadone and buprenorphine.
– Not considered a potent effect.
– Some studies have shown no kinetic effect with 
diazepam and methadone.
• Clonazepam increased oxycodone levels.
– Case report
Jones JD. Drug and Alcohol Dep. 2012.
Burrows DL. J Forensic Sci. 2003.
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Which of the following is true regarding pharmacokinetic 
interactions with opiates and benzodiazepines?
A. Diazepam has shown to increase methadone and 
buprenorphine in some studies but not all.
B. Lorazepam consistently increases blood levels of 
oxycodone.
C. Pharmacokinetic interactions may exist but are not likely 
the major reason for risks associated with combination 
therapy.
D. A and C only.
Assessment Question
15
| |
Which of the following is true regarding pharmacokinetic 
interactions with opiates and benzodiazepines?
A. Diazepam has shown to increase methadone and 
buprenorphine in some studies but not all.
B. Lorazepam consistently increases blood levels of 
oxycodone.
C. Pharmacokinetic interactions may exist but are not likely 
the major reason for risks associated with combination 
therapy.
D. A and C only.
Answer
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• BZD can worsen short term memory.
• In patients using methadone or buprenorphine 
and concomitant BZD working memory (9 
months) worsened compared to baseline.
– Worsened compared to normal controls.
• Methadone a little worse than buprenorphine.
– Diazepam accounted for nearly half of BZD.
Rapeli P. Substance Abuse Treatment, Prevention, Policy. 2009.
Dynamic effect of opiate and BZD on 
memory
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• Increased euphoria ‘high’ compared to opiate 
alone.
– At least 25% of opiate users also use a BZD recently 
and >50% in the last year.
– Diazepam is frequently reported as a preferred agent.
• Often used to diminish opiate withdrawal effect.
– Technically misuse.
DuPont RL. Am J Drug Alcohol. 1988.
Bramness JC. Drug Alcohol Depend. 2007.
Jones JD. Drug Alc Dep. 2012.
Textbook of Psychopharmacology 4th ed. 2009.
Dynamic misuse risk
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Benzodiazepine (BZD) pharmacology
• Abuse seems to be related to a 
combination of all  receptors, 
specifically 1
• BZDs also agonizes opiate receptors
– Primarily  receptors
• Midazolam may have additional  receptor 
agonism.
Ator NA. CNS Spectrums. 2005.
Cox RF. Anesth Analg. 2001.
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• I took 30mg hydrocodone and need help 
falling asleep.  Took 2mg etizolam 10 
minutes ago and plan on feeling good for 
a little while then passing out.  Is this 
combination really that bad?
www.bluelight.org/vb/threads. 25-04-2012.
Bluelight.org
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• I died for almost a minute on the 
combination.
• I really blacked out and woke up from a 
dream realizing I just smashed my car.
• I did 8mg of Xanax and 40mg Opana no 
problem.  I did 13mg of Xanax and 40mg 
Opana and woke up with a doctor staring 
down at me amazed I was still alive.
• I have overdosed and actually died due to 
benzos and opiates.
Bluelight.org - responses
21
| |
• If you know your limits it can go fine.
• If you are tolerant to opiates and benzos, and 
dose accordingly, you are not guaranteed 
death.  Plenty of us combine the two.
• Even now I don’t leave home without 
washing 4mg of clonazepam with methadone 
syrup.
• I usually find the heroin in the UK so weak I 
won’t bother getting heroin unless I got some 
benzos.
Bluelight.org - responses
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Overdose risk 
• OD fatality from opiates (mono) primarily from 
respiratory depression.
– Initiating long acting has higher rates than initiating with short 
acting.
• OD fatality from BZDs (mono) are rare but also from 
respiratory depression, decreased cardiac contractility 
and vasodilation.
• Diazepam, midazolam and flunitrazapam have been 
shown to lower threshold for respiratory depression with 
buprenorphine.
Goldfrank’s Toxicologic Emergencies 10th ed. 2015.
Miller M. JAMA Int Med. 2015.
Jones JD. Drug and Alc Dep. 2012.
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• DAWN network calculated that polypharmacy resulted in a 
37% inc. in having a serious event compared to BZD only.
• 50% of OD involve opiate and BZD.
• Heroin users report up to 80% of their non fatal ODs 
involved a BZD.
• BZDs are involved in 50-80% of methadone related fatal 
ODs.
• 30% of fatal opiate ODs had a concomitant BZD in 2010.
– 77% of fatal BZD ODs also included opiates.
SAMHSA DAWN report. 12/18/2014.
Jones JD. Drug Alc Dep. 2012.
Jones CM. JAMA.2013.
Frequency of OD with opiate and BZD
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BZD and opiate 
• Australian survey in chronic pain pop.
• BZD and opiate combo use correlated with:
– Increased dose of opiate
– Increased use of medical services
• ED visits, ambulance use
• Accidental OD (10% for opiate only v 26% for combo)
– History of substance use disorder diagnosis (387% 
increase) and use of illicit drugs.
Nielsen S. Pain Medicine. 2014.
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Genetic risks
• Genetic differences of the mu opioid 
receptor correlates with risk of toxic OD.
– A118G variation on the mu opiate receptor 
gene results in greater risk of experience 
toxicity.
– Correlates with increased opioid 
requirements.
Manini AF. J Med Toxicol. 2013.
Klepstad P. Acta Anaesthesiol Scand. 2004.
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• Preoperatively
– Hypnotic and analgesic
• Agitation in the ICU
– Ventilated patients
• Few published reports of using both together for 
maintenance purposes.
• Anxiety guidelines rarely recommend the use of daily 
BZDs.  
– Contrarily, chronic pain guidelines do suggest that patients may 
require daily opiate therapy.
• Most warn against combo use.
Benefits of adding opiates and BZDs
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Guideline recommendations
Generalized Anxiety Disorder
• British Association of Psychopharmacology (2014)
– Acute phase
• Start SSRIs, TCAs and add BZD if necessary
– Prophylaxis
• SSRIs, SNRIs, buspirone, pregabalin
• NICE (2007)
– SSRIs for 12 weeks then switch to another for at least 6 mos.
• Benzos for no more than 4 weeks
– Venlafaxine second line (dose 75mg or less)
Guideline recommendations
Generalized Anxiety Disorder
• Canadian Psychiatric Association (2006)
– SSRIs and venlafaxine.
– Second line
• Buspirone, pregabalin, imipramine
• Bupropion XL
– Benzos in the acute phase.
• Have shown long term benefit in some studies.
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LJ is a 35 yo female who is admittedly uses oxycodone 
recreationally.  She has been diagnosed with generalized 
anxiety disorder (GAD) and is expecting to be prescribed 
diazepam.  Which of the following is the most appropriate 
treatment for her GAD?
A. Diazepam is the most appropriate treatment.
B. Initiate escitalopram (an SSRI), low dose and taper up as 
needed.
C. Initiate lorazepam low dose and taper up as necessary.
D. Prescribe the oxycodone on a scheduled basis.
Assessment Question
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LJ is a 35 yo female who is admittedly uses oxycodone 
recreationally.  She has been diagnosed with generalized 
anxiety disorder (GAD) and is expecting to be prescribed 
diazepam.  Which of the following is the most appropriate 
treatment for her GAD?
A. Diazepam is the most appropriate treatment.
B. Initiate escitalopram (an SSRI), low dose and taper up 
as needed.
C. Initiate lorazepam low dose and taper up as necessary.
D. Prescribe the oxycodone on a scheduled basis.
Answer
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Guideline recommendations
Panic Disorder
• British Association for Psychopharmacology (2014)
– Acute phase treatment
• SSRIs, TCAs, venlafaxine
– With BZDs if necessary
– Prophylaxis
• SSRIs, TCAs
• NICE (2007)
– SSRIs for 12 weeks to assess efficacy
• Duration of therapy at least 6 months
– TCAs if multiple SSRIs fail
– BZDs not recommended for prophylaxis
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Guideline recommendations
Panic Disorder
• American Psychiatric Association (APA-2008)
– SSRIs and SNRIs
– TCAs
– BZDs for the first 4-6 weeks of treatment only.
• Canadian Psychiatric Association (2006)
– First line SSRIs and venlafaxine
– Second line TCAs
– BZDs for acute treatment only
Guideline recommendations
PTSD
• British Association of Psychopharmacology (2014)
– Acute
• SSRIs, venlafaxine
– Prophylaxis
• SSRIs
• Augmentation with an atypical antipsychotic, prazosin
• NICE (2005)
– SSRIs and mirtazapine
– TCAs
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Guideline recommendations
PTSD
• APA (2006)
– SSRIs
– TCAs and other antidepressants
– Benzos not recommended as main treatment but as PRN
• VA/DoD (2010)
– SSRIs and SNRIs
– Mirtazapine, TCAs, nefazodone, MAOIs
• Prazosin for nightmares
– No benefit BZDs (harm), valproate, risperidone, topirimate
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• Concomitant use has little data for support in maintenance 
therapy.
• Frequent concomitant use from legal prescriptions and 
obtained illegally.
• Kinetic interactions exist but unlikely to have a dramatic 
impact.
– Watch for CYP 450 3A4 combos
• Dynamic interaction results in substantial reduction in 
respiratory drive.
– Combination often sought after due to dynamic interaction of a 
subjective experience of more intense euphoria.
• Should place more vigilance on concomitant use to verify 
benefit is worth the risk. 
conclusion
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